Zika vaccine candidate enters human safety testing

NCT ID NCT06334393

Completed ⭐️ VACCINE ⭐️ Sponsor: Valneva Austria GmbH Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tested an inactivated Zika virus vaccine (VLA1601) in 150 healthy adults aged 18-49. Participants received two doses, and researchers monitored side effects and immune responses. The goal was to find the safest and most effective dose, including combinations with additional immune-boosting adjuvants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VLA1601 (inactivated Zika virus vaccine with adjuvants)
What this could lead to: If successful, this could lead to a safe and effective vaccine to prevent Zika virus infection, which can cause severe birth defects.
What could go wrong: This is an early Phase 1 trial with only 150 healthy adults, so results may not apply to the general population. The vaccine may not produce a strong enough immune response or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ZIKA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Zika virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ZIKA ZIKA VIRUS INFECTION

Contacts and locations

Locations

Flourish Research

Chicago, Illinois, 60640, United States
Velocity Clinical Research

Sioux City, Iowa, 51106, United States
Velocity Clinical Research

Lincoln, Nebraska, 68510, United States
Velocity Clinical Research

Omaha, Nebraska, 68134, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.